Impact of pharmacist-led interventions on prescribing of SGLT2 inhibitors in hospitalized patients with heart failure

Clicks: 1
ID: 316465
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #90 of 143 articles by views in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 143 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
PURPOSE: The purpose of this study was to evaluate the impact of pharmacist-led interventions on sodium-glucose cotransporter-2 inhibitor (SGLT2i) prescribing in hospitalized patients with heart failure with reduced ejection fraction (HFrEF). METHODS: A quality improvement study was conducted at an academic medical center with 2 phases: a retrospective medication-use evaluation (phase I) and a prospective intervention period (phase II). Phase I assessed eligibility for SGLT2i initiation in hospitalized patients with HFrEF without active study intervention. In phase II, interdisciplinary education on the benefits and place in therapy of SGLT2i was provided. A pharmacist routinely reviewed electronic health records to identify patients eligible for SGLT2i and recommended therapy initiation. The primary endpoint of the study was the percentage of eligible patients on an SGLT2i before and after implementation of pharmacist intervention. Secondary endpoints included 30-day all-cause and heart failure readmission rates, the quantity and acceptance rate of pharmacist interventions, and the incidence of adverse outcomes. RESULTS: Among 150 patients in phase I and 133 patients in phase II, 123 and 94 were eligible for SGLT2i therapy, respectively. The overall frequency of inpatient SGLT2i prescribing significantly increased from phase I to phase II (38.2% vs 68.1%, respectively; P < 0.001). Continuation of outpatient SGLT2i therapy during hospitalization also improved after implementation of pharmacist intervention (from 16.3% to 36.2%; P = 0.001). There were no differences in readmission rates or the incidence of adverse events. The acceptance rate for pharmacist interventions was 50%. CONCLUSION: Increased prescribing of SGLT2i therapy in hospitalized patients with heart failure was observed following pharmacist-led education and prospective reviews with feedback.
Reference Key
openalex_W7164026006 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Nnenna Anyanwu, Dana Serao, Polly Jen, Marc Cohen, Kayla Torppey
Journal American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Year 2026
DOI
10.1093/ajhp/zxag158
URL
https://doi.org/10.1093/ajhp/zxag158
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.